T. Sebastian, S. Rajeeve, T. Farzana, R. Firestone, E. Jurgens, K. Miller, B. Costa, A. Lesokhin, C. Tan, G. Shah, N. Korde, H. Landau, M. Scordo, H. Hassoun, K. Maclachlan, U. Shah, M. Hultcrantz, A. Derkach, D. Nemirovsky, S. Giralt, S. Z. Usmani, S. Mailankody, H. Hashmi
{"title":"daratumumab的难治性对CAR - t细胞治疗复发难治性多发性骨髓瘤后临床结果的影响","authors":"T. Sebastian, S. Rajeeve, T. Farzana, R. Firestone, E. Jurgens, K. Miller, B. Costa, A. Lesokhin, C. Tan, G. Shah, N. Korde, H. Landau, M. Scordo, H. Hassoun, K. Maclachlan, U. Shah, M. Hultcrantz, A. Derkach, D. Nemirovsky, S. Giralt, S. Z. Usmani, S. Mailankody, H. Hashmi","doi":"10.1038/s41408-025-01343-4","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"146 1","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma\",\"authors\":\"T. Sebastian, S. Rajeeve, T. Farzana, R. Firestone, E. Jurgens, K. Miller, B. Costa, A. Lesokhin, C. Tan, G. Shah, N. Korde, H. Landau, M. Scordo, H. Hassoun, K. Maclachlan, U. Shah, M. Hultcrantz, A. Derkach, D. Nemirovsky, S. Giralt, S. Z. Usmani, S. Mailankody, H. Hashmi\",\"doi\":\"10.1038/s41408-025-01343-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"146 1\",\"pages\":\"\"},\"PeriodicalIF\":11.6000,\"publicationDate\":\"2025-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-025-01343-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-025-01343-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as:
Preclinical studies of new compounds, especially those that provide mechanistic insights
Clinical trials and observations
Reviews related to new drugs and current management of hematologic malignancies
Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.